Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
By Angelica Peebles,
CNBC
| 02. 21. 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money.
Bluebird’s shareholders will receive $3 per share with the possibility of getting another $6.84 a share if Bluebird’s gene therapies reach $600 million in sales in any 12-month period by the end of 2027. Bluebird shares closed at $7.04 on Thursday. They fell 40% on Friday after the company announced the sale.
For more than thirty years, Bluebird has been at the forefront of creating one-time treatments that promised to cure genetic diseases. At one point, Bluebird’s market cap hovered around $9 billion as investors bought into the idea that the company could find success with its gene therapies. It’s fallen under $41 million after the company faced several scientific setbacks, separated its cancer work into another company and fell into financial despair.
The turning point came in 2018, when Bluebird...
Related Articles
By Darren Incorvaia, Fierce Biotech | 05.28.2025
An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of...
Last week, May 21–23, a broad range of experts gathered in Boston to discuss the future of powerful biotechnologies with the potential to change what it means to be human. The fourth in a series of international Summits on human genome editing, this event was organized by the Global Observatory for Genome Editing, which “seeks to expand the range of questions arising at the frontiers of emerging biotechnologies … and fosters international, interdisciplinary, and cross-sectoral dialogue.” Like previous Summits...
By Caiwei Chen and Antonio Regalado , MIT Technology Review | 05.23.2025
Since the Chinese biophysicist He Jiankui was released from prison in 2022, he has sought to make a scientific comeback and to repair his reputation after a three-year incarceration for illegally creating the world’s first gene-edited children.
While he has...
By Kevin Davies, Genetic Engineering & Biotechnology News | 05.21.2025
This week a diverse group of researchers, bioethicists, publishers and theologians, are gathering in Cambridge, Massachusetts, to extend and expand the rolling debate about the merits of human heritable genome editing (HHGE). The international summit is being hosted by the...
